In particular, its synergistic activity with other anti-tumoral treatments, such as chemotherapy and radiotherapy [37–39] or with other molecular targets related to tumor growth and proliferation, including VEGFR or aromatase inhibitors [40–42] has been often highlighted. The gene discussed is CYP19A1; the disease is neoplasm.